Dong‐Wan Kim

32.9k total citations · 11 hit papers
364 papers, 21.5k citations indexed

About

Dong‐Wan Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dong‐Wan Kim has authored 364 papers receiving a total of 21.5k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Oncology, 248 papers in Pulmonary and Respiratory Medicine and 56 papers in Molecular Biology. Recurrent topics in Dong‐Wan Kim's work include Lung Cancer Treatments and Mutations (219 papers), Lung Cancer Research Studies (103 papers) and Colorectal Cancer Treatments and Studies (71 papers). Dong‐Wan Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (219 papers), Lung Cancer Research Studies (103 papers) and Colorectal Cancer Treatments and Studies (71 papers). Dong‐Wan Kim collaborates with scholars based in South Korea, United States and Spain. Dong‐Wan Kim's co-authors include Dae Seog Heo, Enriqueta Felip, Myung‐Ju Ahn, Tae Min Kim, Ji‐Youn Han, Joo-Hang Kim, Edward B. Garon, Gilberto de Castro, Roy S. Herbst and Mary J. Fidler and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Dong‐Wan Kim

354 papers receiving 21.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2015 4.9k citations Dong‐Wan Kim, Enriqueta Felip et al. profile →
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

2017 1.6k citations Alice T. Shaw, Jin Seok Ahn et al. profile →
Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes

2006 1.6k citations Dong‐Wan Kim et al. profile →
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 656 citations Sae‐Won Han, Tae‐You Kim et al. Journal of Clinical Oncology profile →
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Todd M. Bauer et al. profile →
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

2017 430 citations Dong‐Wan Kim, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations James Chih‐Hsin Yang, Dong‐Wan Kim et al. Journal of Clinical Oncology profile →
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

2018 225 citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Dong‐Wan Kim

Since Specialization

Citations

This map shows the geographic impact of Dong‐Wan Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dong‐Wan Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dong‐Wan Kim more than expected).

Fields of papers citing papers by Dong‐Wan Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dong‐Wan Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dong‐Wan Kim. The network helps show where Dong‐Wan Kim may publish in the future.

Co-authorship network of co-authors of Dong‐Wan Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Dong‐Wan Kim. A scholar is included among the top collaborators of Dong‐Wan Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dong‐Wan Kim. Dong‐Wan Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preferential Sensitivity of the <i>EGFR</i> L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer 2025 ·Cancer Research and Treatment ·(unknown), Sheehyun Kim, Soyeon Kim, (unknown), Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Jeonghwan Youk	0
2	Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications 2025 ·ESMO Open ·Changhee Park, Rathana Kim, Jae Moon Bae, Taebum Lee, Si Yeol Song, Yoonjin Kwak, Lee Kb, Jeonghwan Youk, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Jong‐Il Kim, Jaeyong Choi, Miso Kim	1
3	In Situ Formation of Bifunctional Interlayer on 3D Conductive Scaffold for Dendrite‐Free Li Metal Batteries 2025 ·Energy & environment materials ·(unknown), (unknown), Minjun Bae, (unknown), (unknown), Hwichan Hong, (unknown), Dong‐Wan Kim, Jeongyeon Lee, Yuanzhe Piao	2
4	Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study 2024 ·BMJ Open ·Chia‐Chi Lin, Giuseppe Curigliano, Armando Santoro, Dong‐Wan Kim, David Tai, F. Stephen Hodi, Sofie Wilgenhof, Toshihiko Doi, Catherine Sabatos-Peyton, Sebastian Szpakowski, Shripad Chitnis, Alexandros Xyrafas, Sabine Gutzwiller, Alessandro Pastore, Nicolas Mach	8
5	Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM) 2024 ·Journal of Clinical Oncology ·Sehhoon Park, (unknown), Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Yu Jung Kim, Youngjoo Lee, Dong‐Wan Kim, Sang‐We Kim, Ki Hyeong Lee, Won-Jae Lee, Jung Won Choi, Kyuha Chong, Jung-Il Lee, (unknown), Nak‐Hoon Son, Myung‐Ju Ahn	23
6	Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Gerald S. Falchook, Patricia LoRusso, Jonathan W. Goldman, Anthony B. El-Khoueiry, Anthony W. Tolcher, Yan Xing, Jason T. Henry, Bhumsuk Keam, Dong‐Wan Kim, Tae-Yong Kim, (unknown), Min Hee Hong, Min Hwan Kim, (unknown), Sang Mi Lee, (unknown), John W. Hayslip, Cong Xu, Edward B. Garon	4
7	Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. 2024 ·Journal of Clinical Oncology ·Pasi A. Jänne, (unknown), Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Kaline Pereira, (unknown), Ayumi Taguchi, Yingkai Cheng, Kōichi Goto	4
8	Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study breakdown → 2024 ·Journal of Clinical Oncology ·Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer	118
9	ASTRONAUT SELECTION AND POTENTIAL RISK MANAGEMENT: PSYCHOLOGICAL TRAUMA AND RESILIENCE FOR MARS SPACE MISSION 2024 ·Trames Journal of the Humanities and Social Sciences ·Dong‐Wan Kim	0
10	Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis 2023 ·Clinical Cancer Research ·Chong Kin Liam, (unknown), Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, (unknown), Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu	22
11	Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer 2021 ·Thoracic Cancer ·Eun Hee Jung, (unknown), Se Hyun Kim, Koung Jin Suh, Yu Jung Kim, Ju Hyun Lee, Jin‐Haeng Chung, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo, Jong Seok Lee	12
12	Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11) 2021 ·Cancer ·Hong-Sik Kim, Dong‐Wan Kim, Miso Kim, Youngjoo Lee, Hee Kyung Ahn, Jang Ho Cho, Il Hwan Kim, Yun‐Gyoo Lee, Seong Hoon Shin, Song Ee Park, (unknown), Eun Joo Kang, Myung‐Ju Ahn	30
13	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines 2020 ·Journal for ImmunoTherapy of Cancer ·Ji‐Eun Park, Seong‐Eun Kim, Bhumsuk Keam, (unknown), Soyeon Kim, Miso Kim, Tae Min Kim, Junsang Doh, Dong‐Wan Kim, Dae Seog Heo	72
14	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07 2020 ·Thoracic Cancer ·Miso Kim, Bhumsuk Keam, Chan‐Young Ock, Se Hyun Kim, Yu Jung Kim, Sun Min Lim, Jin‐Soo Kim, Tae Min Kim, Sook Hee Hong, Mi Sun Ahn, Seong Hoon Shin, Eun Joo Kang, Dong‐Wan Kim, (unknown), Jong‐Il Kim, Jong Seok Lee, Joo‐Hang Kim, Dae Seog Heo	19
15	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer 2018 ·Yonsei Medical Journal ·(unknown), Se Hyun Kim, Yu Jung Kim, Joo Hyun Lee, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo, Jin-Haeng Chung, Yoon Kyung Jeon, Jong Seok Lee	7
16	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity breakdown → 2016 ·Clinical Cancer Research ·Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, (unknown), Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross	523
17	Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors 2016 ·Cancer Immunology Research ·Yaewon Yang, (unknown), Tae Min Kim, Yong‐Oon Ahn, Hana Choi, (unknown), Bokyung Min, Jung Hyun Her, (unknown), Bhumsuk Keam, Se‐Hoon Lee, Dong‐Wan Kim, Yu Kyeong Hwang, Dae Seog Heo	128
18	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration 2016 ·Clinical Cancer Research ·Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Ju‐Seog Lee, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong‐Wan Kim, Doo Hyun Chung, Dae Seog Heo	201
19	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity 2010 ·Clinical Cancer Research ·Zachary C. Hartman, Jun-Ping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, (unknown), (unknown), Dong‐Wan Kim, Wenle Xia, Neil L. Spector, Jeffrey R. Marks, William T. Barry, Amy Hobeika, Gayathri R. Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, Timothy M. Clay	21
20	Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation 2006 ·Clinical Cancer Research ·Sae‐Won Han, Tae‐You Kim, Yoon Kyung Jeon, Pil Gyu Hwang, Seock‐Ah Im, Kyung-Hun Lee, Jee Hyun Kim, Dong‐Wan Kim, Dae Seog Heo, Noe Kyeong Kim, Doo Hyun Chung, Yung‐Jue Bang	196

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact